Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Inv. presentation
Quarterly results
Director comp.
Appointed director
23andMe Holding Co. Create: Alert

All | News | Filings
Date FiledTypeDescription
10/10/2023 8-K Quarterly results
10/05/2023 144 Form 144 - Report of proposed sale of securities:
08/24/2023 144 Form 144 - Report of proposed sale of securities:
08/08/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/08/2023 8-K Quarterly results
Docs: "23andMe Reports FY2024 First Quarter Financial Results Reaffirmed Full Year Revenue Guidance and Raised Full Year Guidance for Net Loss and Adjusted EBITDA Deficit Webcast at 4:30 pm ET, August 8, 2023 SOUTH SAN FRANCISCO, Calif., August 8, 2023"
08/04/2023 DEFR14A Form DEFR14A - Revised definitive proxy soliciting materials:
07/27/2023 144 Form 144 - Report of proposed sale of securities:
07/26/2023 DEFR14A Form DEFR14A - Revised definitive proxy soliciting materials:
07/26/2023 ARS Form ARS - Annual Report to Security Holders:
07/26/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
07/26/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
06/29/2023 144 Form 144 - Report of proposed sale of securities:
06/09/2023 8-K Cost Associated with Exit or Disposal Activities  Interactive Data
05/25/2023 10-K Annual Report for the period ended March 31, 2023
05/25/2023 8-K Quarterly results
Docs: "23andMe Reports FY2023 Fourth Quarter and Full Year Financial Results Achieved FY2023 financial guidance FY2023 full year revenue grew 10% over prior year Webcast today, May 25, 2023 at 4:30 p.m. Eastern Time SOUTH SAN FRANCISCO, Calif., May 25, 2023 -- 23andMe Holding Co. , a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, today reported its financial results for the fourth quarter and full year of fiscal year 2023 , which ended March 31, 2023. 23andMe is the only company with multiple U.S. Food and Drug Administration authorizations for over-the-counter genetic health risk reports. The Company has also created the world’s largest, re-contactable crowdsourced platform of genotypic information paired ..."
04/17/2023 8-K Quarterly results
04/14/2023 8-K Quarterly results
03/02/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
03/02/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
02/14/2023 SC 13G NewView Capital Fund I, L.P. reports a 6.8% stake in 23andMe Holding Co.
02/13/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
02/09/2023 SC 13G VANGUARD GROUP INC reports a 9.5% stake in 23andMe Holding Co. Class A
02/09/2023 SC 13G/A FMR LLC reports a 3.7% stake in 23ANDME HOLDING CO
02/08/2023 10-Q Quarterly Report for the period ended December 31, 2022
02/08/2023 8-K Quarterly results
02/06/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Sales Agreement by and between 23andMe Holding Co. and Cowen and Company, LLC, (incorporated by reference to Exhibit 1.2 to 23andMe Holding Co.’s Registration Statement on Form S-3 filed on February 6, 2023)"
02/06/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
01/20/2023 SC 13D/A GSK PLC reports a 12.2% stake in 23ANDME HOLDING CO.
12/09/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Second Amended and Restated Bylaws of 23andMe Holding Co",
"23andMe Holding Co. Change in Control Separation Plan"
12/07/2022 144 Form 144 - Report of proposed sale of securities:
11/09/2022 8-K Investor presentation
Docs: "2 3 4 1 JAMA,"
11/09/2022 EFFECT Form EFFECT - Notice of Effectiveness:
11/07/2022 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
11/07/2022 10-Q Quarterly Report for the period ended September 30, 2022
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy